HUTCHMED (China) Limited

– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO ₂ as the primary endpoint – – STRATUS-HCM on track to start in the fourth quarter of 2026 – BOULDER, Colo., Nov. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced favorable feedback from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for EDG-7500 in symptomatic obstructive and nonobstructive hypertrophic cardiomyopathy (HCM).

— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —

— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio's cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers: